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Abstract In 2011, the European League Against
Rheumatism (EULAR) published recommendations regard-
ing the vaccination of children with rheumatic diseases.
These recommendations were based on a systematic literature
review published in that same year. Since then, the evidence
body on this topic has grown substantially. This review pro-
vides an update of the systematic literature study of 2011,
summarizing all the available evidence on the safety and
immunogenicity of vaccination in paediatric patients with
rheumatic diseases. The current search yielded 21 articles, in
addition to the 27 articles described in the 2011 review. In
general, vaccines are immunogenic and safe in this patient
population. The effect of immunosuppressive drugs on the
immunogenicity of vaccines was not detrimental for
glucocorticosteroids and methotrexate. Biologicals could ac-
celerate a waning of antibody levels over time, although most
patients were initially protected adequately. Overall, persis-
tence of immunological memory may be reduced in children
with rheumatic diseases, which shows the need for (booster)
vaccination. This update of the 2011 systematic literature
review strengthens the evidence base for the EULAR recom-
mendations, and it must be concluded that vaccinations in
patients with rheumatic diseases should be advocated.
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Introduction
Children with paediatric rheumatic diseases (pedRD) have an
increased risk of infection, which contributes to the mortality
and morbidity of their disease [1–3]. Effective and safe vacci-
nation is key in prevention of numerous of these infections.
Assessing efficacy of a vaccine in patients with pedRDs is
challenging. The ideal measure of efficacy, infection rates, is
usually not studied as a primary endpoint because this requires
large sample sizes. Surrogate measures such as immunogenic-
ity are commonly used instead. Immunogenicity refers to the
immune response induced by vaccination. This is usually
measured by vaccine-specific geometric mean antibody titers
(GMT) or concentrations (GMC), seroconversion rates and/or
seroprotection rates. The measure for immunogenicity differs
per vaccine, as the relation between the humoral and/or cellu-
lar immune response and protection differs per pathogen
[4–6]. Immunogenicity of a vaccine in patients with rheumatic
diseases can differ from the healthy population, due to the
disease or its immunosuppressive treatment.
Besides short-term vaccine-induced immune responses,
persistence of protective immunologic memory after vaccina-
tion is essential in preventing infections [7, 8]. As this persis-
tence goes beyond follow-up of most studies in rheumatic
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diseases, long-term effectiveness of most vaccines is
unknown.
The safety of vaccines in pedRD can be addressed on dif-
ferent levels: adverse event rate in comparison to healthy con-
trols, increased disease activity induced by vaccination and
unintentional infections induced by live-attenuated pathogens
in vaccines (especially in patients on high-dose immunosup-
pressive drugs). Another issue of vaccine safety is whether
vaccines or their constituents can actually cause autoimmune
disease (AID), which will be addressed briefly.
Over the years, awareness of infection prevention by vac-
cination in rheumatic diseases has increased. In 2011, a
EULAR task force published evidence-based recommenda-
tions regarding vaccination of adults and children with rheu-
matic diseases. A year later, the Brazilian Society of
Rheumatology published vaccination recommendations for
patients with rheumatoid arthritis (RA) [9, 10, 11••].
According to these recommendations, non-live vaccines
are generally adequately immunogenic and safe. Live-
attenuated vaccines can be administered to patients with
pedRD, unless they are on high-dose immunosuppressive
drugs or biologicals. In these cases, evidence on safety is
scarce but reassuring. Therefore, live-attenuated booster vac-
cinations can be considered on individual basis.
Not all vaccines have been studied in pedRD patients, most
studies do not take persistence of immunological memory into
account, and studies were often underpowered and uncon-
trolled to assess safety. Consequently, concerns regarding ef-
ficacy and safety of vaccines remain. Providing a periodical
overview of new evidence, as advised in the EULAR recom-
mendations, is necessary to assure effective and safe vaccina-
tion in this vulnerable group.
In this review, we provide an update of the evidence on
vaccination of pedRD patients published since the EULAR
recommendations in 2011 [12••]. The influence of immuno-
suppressive drugs and biologicals on immunogenicity and
safety of non-live composite as well as live-attenuated vac-
cines will be addressed. Additionally, we describe the use of
adjuvants and their possible association with adverse events
(AE).
A systematic literature review was performed in July 2014,
following the methodology described earlier [12••]. Since the
first systematic literature review describing 27 papers, 21 ad-
ditional eligible articles on vaccination of patients with pedRD
have been published (Fig. 1). A large portion (n=10) of the
new studies investigated the immunogenicity of the seasonal
influenza or H1N1 vaccine. The pedRD studied most (n=13)
was juvenile idiopathic arthritis (JIA). Eleven new studies
described the influence of biologicals on immunogenicity of
the vaccine, adding to the five studies described earlier. Three
additional articles were found which studied live-attenuated
vaccines to the six articles included in 2011. Two new studies
were randomized controlled trials (RCTs). This is the study
design of choice when assessing the effect of vaccination on
disease activity in pedRD [13••, 14••].
Vaccine Immunogenicity in Paediatric Patients With
Rheumatic Diseases
Most studies assessed short-term vaccine-induced immunoge-
nicity. Five studies measured antibody levels up to 12 months
post-vaccination [13••, 14••, 15–17]. Another five studies
evaluated antibody persistence several years after vaccination
[18–22]. Although some studies studied actual occurrence of
infections such as herpes zoster (HZ) or influenza, they were
underpowered to assess these outcomes reliably [13••, 23, 24].
Below we summarize and discuss all available evidence
found in the previous and current systematic literature [12••].
Fig. 1 The search strategy for the systematic literature review [12••]. The
disease search encompassed articles on vaccination in patients with
paediatric autoinflammatory or rheumatic diseases, and the medication
search encompassed articles on vaccination and immunosuppressive
drugs
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Immunogenicity in Relation to Immunosuppressive Drugs
Glucocorticosteroids
Eleven articles included 401 patients using glucocorticosteroids
(GC). Of them, the majority used a low dose (<20 mg/day) [17,
18, 25–27, 29–32, 43] (Table 1). Patients who use GC may
show lower seroconversion rates or GMT, but they generally
still reach protective antibody titers. A high dose of GC or
concomitant use of other immunosuppressive drugs was asso-
ciated with lower, yet still protective, responses in several stud-
ies. No effect of GC on the persistence of several vaccine-
specific antibodies (mumps, measles and rubella vaccine
(MMR), tetanus-diphtheria vaccine (TD)) could be found in
one study [18]. These findings show that there is no general
detrimental effect of low-dose GC on immunogenicity or
established antibody levels.
Methotrexate
Eight studies including 420 patients on methotrexate (MTX)
were available [18, 20, 26, 27, 33–36] (Table 1). No effect of
MTXwas found on short-term immunogenicity of vaccines or
on the persistence of antibodies over time [18, 22].
Biologicals
A total of 296 patients using biologicals were included in 15
studies [13••, 14••, 21–24, 28, 34–41] (Table 1). The biolog-
icals most frequently studied were tumour necrosis factor
(TNF)α blockers. The majority of patients reached protective
antibody concentrations after vaccination, but in the majority
of studies the actual antibody concentrations of patients using
biologicals were lower than of patients who did not.
Additionally, the antibody levels declined more rapidly over
time in patients using biologicals [22, 41]. A lower initial
GMT and a more rapid decline in antibody levels will lead
to a quicker decrease in seroprotection rate in these patients.
Monitoring GMTs and additional booster vaccinations should
be considered in order to ensure protection in these patients.
Another option is to administer specific vaccines prior to start
of biological therapy.
Immunogenicity of Non-live Composite Vaccines
Human Papillomavirus Vaccine
Currently, there are two human papilloma virus (HPV) vac-
cines: the quadrivalent (qHPV) vaccine (against HPV 6, 11,
16 and 18) and the bivalent (bHPV) vaccine (against HPV 16
and 18). At the time the EULAR recommendations were pub-
lished, no publications regarding the immunogenicity or safe-
ty of either HPV vaccine in pedRD were available. The
recommendation was based on preliminary data [10]. Since
then, three articles assessing the immunogenicity and safety of
the HPV vaccine in pedRD have been published [15, 16, 52]
(Table 2).
The immunogenicity of the bivalent vaccine in 63 JIA pa-
tients was compared to 48 healthy controls, showing that all
participants were seropositive up to 12 months after vaccina-
tion. GMCs were lower in patients than in controls, but no
statistical significant difference in GMC over time was found
[15].
Adequate immunogenicity of HPV vaccination is of spe-
cific interest in patients with systemic lupus erythematosus
(SLE), as these patients have a high risk of persistent HPV
infections [62–64]. Two studies included a total of 33 juvenile
SLE (jSLE) patients, one including a control group of 49
healthy children. Both studies showed that the majority of
patients seroconverted [16, 52]. Interestingly, the pilot study
including six jSLE patients reported lower antibody concen-
trations in patients than in controls [16]. A study in 39 adult
SLE patients also showed lower GMCs in patients than in
healthy controls [65]. Based on these results, the long-term
protection against HPV infections in SLE patients is unclear.
Larger, controlled studies in jSLE patients are necessary to
assess the immunogenicity of the HPV vaccine in this group.
Seasonal Influenza Virus and H1N1 Vaccine
Fifteen articles described the immunogenicity of seasonal in-
fluenza and H1N1 vaccines in pedRD (Table 2). They includ-
ed 899 pedRD patients [23, 24, 27–29, 31, 32, 35, 36, 41–43,
56, 58]. One study group described a similar study population
in three articles [31, 36, 58]. The three overlapping studies are
described separately in Table 2, as it was impossible to disen-
tangle the data.
Although antibody concentrations in patients were lower,
seroprotection against influenza was similar in patients and
controls. Two studies including 209 jSLE patients showed that
this specific group has significantly lower seroconversion rates,
seroprotection rates and GMT than healthy controls. Lower
responses were not related to medications used and were pos-
sibly associated with a higher SLE disease activity index [32].
Two studies assessed the incidence of respiratory infections
and influenza-like illness. Due to their small study population,
no definite conclusions could be drawn regarding vaccine ef-
ficacy [23, 24].
Hepatitis A and hepatitis B Vaccine
One new study on the immunogenicity of the hepatitis Avirus
(HAV) vaccine was found [54]. Two studies including 57
patients showed an adequate immunogenicity in patients not
using anti-TNFα treatment [40, 53]. One study in twelve chil-
dren with inflammatory bowel syndrome using anti-TNFα
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treatment showed an adequate seroconversion rate of 92 %
[54] (Table 2).
Hepatitis B virus (HBV) vaccines were studied in 245 pa-
tients [19, 21, 26, 30, 53] (Table 2). After vaccination, the
majority of the patients and all of the healthy controls had
protective antibody levels. However, the persistence of protec-
tive immunity against HBV may be lower in pedRD patients
[19, 21]. The reduced proportion of patients that is protected
directly after vaccination, together with the low percentage of
protected patients several years after vaccination, illustrates
that the humoral response after HBV vaccination should be
checked and that patients could benefit from a booster vaccine.
Meningococcal Vaccine
One new study was found, in addition to the previously de-
scribed study on the Neisseria meningitides C (NeisVac-C)
vaccine, which was safe and immunogenic in 234 JIA patients
[22, 59] (Table 2). In this study, MenC-IgG levels were
assessed over time in 127 patients with JIA and 1527 healthy
controls [22]. IgG levels decreased over time, with a faster
decline in younger patients. Four years after vaccination,
MenC-IgG levels in JIA patients were similar to those in
healthy controls. Patients who had started biologicals showed
an accelerated decline in antibody levels.
Pneumococcal Vaccines
No new studies were found on pneumococcal vaccines. In the
previous review, one study was found (Table 2). It showed that
JIA patients had a similar response and seroprotection rate to
the 7-valent pneumococcal vaccine (PCV7) as healthy con-
trols when using MTX or cyclosporine, either with or without
concomitant GC use. Patients using anti-TNFα were all
seroprotected, but had significantly lower antibody concentra-
tions [39].
Tetanus-Diphtheria Vaccine
One new study was added to the evidence from four studies
previously found on immunogenicity of the tetanus toxoid
(TT) or tetanus-diphtheria (TD) vaccine [20, 55, 60,
61] (Table 2). The previously found studies (95 patients, 125
controls) showed comparable antibody levels to controls. Two
studies in 430 pedRD patients assessed persistence of these
antibodies over time. Both showed lower concentrations and
seroprotection rates than in a comparable healthy control
group after 7–16 years of follow-up [18, 20].
Other Non-live Composite Vaccines
No articles were found containing information onHaemophilus
influenza type B (HiB) vaccines, pertussis vaccines or
inactivated poliovirus vaccines. No information was found on
vaccines indicated for endemic areas such as vaccines against
typhoid fever, tick-borne encephalitis (FSME), rabies, Japanese
encephalitis or cholera.
Live-Attenuated Vaccines
Measles, Mumps and Rubella Vaccine
In the previous systematic literature review, only one
study in ten JIA patients assessed short-term immunoge-
nicity of the MMR booster. It showed a cellular and hu-
moral immune response comparable to healthy controls
[34]. One additional article on the immunogenicity of
the MMR booster vaccination was published. This RCT
showed that all 68 vaccinated patients displayed a signif-
icant increase in MMR antibody concentrations. All pa-
tients were seroprotected against MMR at 12 months after
vaccination [14••] (Table 2).
Two studies reported on the persistence of antibodies sev-
eral years after MMR vaccination in patients with JIA or
jSLE. Both studies found similar levels of protective antibod-
ies against measles in patients and controls 7–16 years after
two MMR doses in the first year of life [20] and in all age
groups (1–19 years) after one or two MMR doses. Protective
antibody levels against mumps and rubella up to 10 years after
MMR booster vaccination were significantly lower in JIA
patients than in controls. Patients had an odds ratio of 0.4 to
be seroprotected against mumps or rubella compared to con-
trols (adjusted for age and number of vaccinations) [18]
(Table 2).
Varicella Zoster Vaccine
In the previous review, two studies regarding the varicella
zoster virus (VZV) vaccine were found. A controlled study
including 25 pedRD patients and 18 healthy controls found a
lower response rate in patients than in controls after vaccina-
tion. Of the eight patients who reported having contact with a
VZV-infected individual, two (both non-responders), devel-
oped chickenpox [17]. A case series reported six IBD patients
having positive immunity after vaccination [38]. One new
study, an RCT including 54 jSLE patients of whom 28 were
vaccinated, has been found in the new search. Only patients
who used either cyclosporine, azathioprine, methotrexate and/
or GC up to 20 mg/day were included in this study. All par-
ticipants had protective antibody levels against VZV at base-
line. Patients had a similar increase in GMT as the healthy
control group, and all had a significant increase in antibody
levels compared to baseline. Over 35.6 months of follow-up
after vaccination, four cases of HZ were reported in the un-
vaccinated group whereas no HZ occurred in the vaccinated
group [13••] (Table 2).
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In adults, two large studies illustrate the importance of ef-
fective vaccination against VZV. A meta-analysis in adults
with rheumatic diseases (RD) showed that the risk of HZ
infections is increased by up to 61 % in patients using biolog-
icals compared to patients using conventional disease-
modifying anti-rheumatic drugs (DMARDs) [66]. A retro-
spective cohort study in 7780 vaccinated and 455,761 unvac-
cinated adults with RD assessed vaccine efficacy (incidence of
HZ infections >42 days after vaccination). They showed a
significantly lower hazard ratio for HZ infections (HR 0.61,
95 % CI 0.59–0.75) in vaccinated patients up to 2 years of
follow-up [67•].
Bacillus Calmette-Guérin Vaccine
No new evidence was found on the immunogenicity of the
Bacillus Calmette-Guérin (BCG) vaccine in pedRD pa-
tients [27, 44–49] (Table 2). In the 2011 review, seven
papers were described including 15,810 Kawasaki disease
(KD) patients and 115 JIA patients. It is suggested that JIA
patients have lower protection rates after vaccination, due
to their lower tuberculin skin test induration size. The re-
maining articles did not assess immunogenicity. As the
vaccine causes local inflammation at the BCG vaccination
site in up to 50 % of KD patients, withholding the BCG
vaccine in active KD was advised [11••].
Yellow Fever Vaccine
No studies were found on the immunogenicity of the yellow
fever (YF) vaccine in children with pedRD, but it has been
studied in 91 adult patients with RD. In these patients, the
vaccine had good immunogenicity. The responses were re-
duced in the 26 patients who used anti-TNFα therapy [71].
The EULAR stated that booster vaccinations against YF can
be considered in patients onMTX less than 15mg/m2/week or
low-dose GC [12••].
Vaccine Safety in Paediatric Patients With
Rheumatic Diseases
Adverse Events and Serious Adverse Events
Adverse events (AE) and serious adverse events (SAE) were
registered in the majority of the studies. None found relevant
differences in AE between patients and controls and no SAE
related to vaccination were reported.
Preliminary data on thromboembolic events after qHPV
vaccination resulted in the EULAR recommendation to be
vigilant for these complications [11••]. Based on current liter-
ature, this seems unnecessary as a large cohort study in 997,
585 healthy girls, of whom 296,826 received at least one dose
of the qHPV vaccine, showed no evidence of an association
between qHPV vaccination and venous thromboembolic ad-
verse events [68•].
Disease Activity Induced by Vaccination
As most pedRD are very unpredictable in disease activity and
flares, the only reliable method to assess the effect of vacci-
nation on disease activity is an RCT study design. This way,
results are corrected for the relapsing-remitting course of the
disease. Two RCTs assessed the effect of the live-attenuated
MMR booster vaccination on JIA, respectively, the VZV vac-
cination on jSLE disease activity. Both studies reported simi-
lar disease activity and flare rates in vaccinated patients and
disease-controls [13••, 14••]. Some non-randomized studies
included an unvaccinated control group of patients. These
studies suffered from selection bias since the unvaccinated
group had lower disease activity at baseline [24] or the control
group was not described at all [30].
Most studies assessing disease activity used patients as
their own control. These studies reported a stable disease ac-
tivity over time or similar flare rates before and after vaccina-
tion (Table 2). One case report described a systemic onset JIA
(soJIA) patient on anti-IL6 who received two seasonal influ-
enza vaccines and had a disease flare after both vaccinations
[57]. In contrast, a study in 27 soJIA patients using anti-IL6
receiving a seasonal influenza vaccine did not show any ex-
acerbations [42]. In summary, studies do not show an increase
in disease activity after vaccinations in the patient population
as a whole. This is unequivocally shown by the RCTs with
live-attenuated vaccines. Of course, the theoretical possibility
remains that individual patients are susceptible for aggrava-
tion of disease after vaccination due to disproportionate im-
mune responses. However, this theoretic possibility should
not result in refraining from current immunization practice,
because the benefits of infection prevention significantly out-
weigh the small risk of a disease flare in patients.
Induction of Infections With Attenuated Pathogens
The possibility of the induction of infections with an attenu-
ated pathogens after live-attenuated vaccines is a matter of
concern especially in patients on high-dose immunosuppres-
sive drugs or biologicals. Only the RCTassessing the safety of
the live-attenuated MMR vaccine included patients using bi-
ologicals (n=9). They did not have infections with the live-
attenuated pathogens [14••]. A cohort study including 25
VZV-vaccinated pedRD patients showed no overt varicella
episodes within 40 days after vaccination. Three patients did
develop a mild, self-limiting varicella-like rash, but this was
not accompanied by any other symptoms [17]. A study in
7780 adult patients with RD reported 11 HZ cases within
42 days after vaccination, suggestive for vaccination-induced
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herpes infections [67•]. Reassuringly, no vaccination-induced
HZ infections were detected in the 633 patients on biologicals.
Information on the BCG vaccination in patients on high-
dose immunosuppressive drugs or biologicals is lacking.
There is a very high rate of complications in patients who
are severely immunocompromised, such as SCID patients
[69]. One case report described a 3-month-old infant born to
a mother with Crohn’s diseases using infliximab who had a
lethal vaccination-induced mycobacterial infection after BCG
vaccination [70]. Based on these data, BCG vaccines should
therefore not be administered to patients using biologicals or
high doses of immunosuppression.
There is no information available on the safety of the live-
attenuated YF vaccine in patients with pedRD, but the vaccine
was safe in adult patients with RD [71].
Adjuvant Safety in Paediatric Patients With
Rheumatic Diseases
Adjuvants are added to vaccines to enhance the immune re-
sponse to the vaccine-antigen. Frequently used adjuvants (al-
um, Toll-like receptor (TLR) four ligand monophosphoryl lip-
id A adsorbed to alum (ASO4) and oil in water emulsions like
AS03 or MF59) stimulate pattern-recognition receptors
(PRRs) such as TLRs. TLRs are expressed on cells like den-
dritic cells, which in turn determine the magnitude and quality
of the adaptive immune response [72–74]. Through these
mechanisms, adjuvants could theoretically also trigger or en-
hance autoimmune responses in patients with established AID
[74, 75].
The safety of adjuvants in rheumatic diseases has not
been studied well. RCTs, in which patients with rheumatic
diseases are vaccinated with adjuvanted versus unadjuvanted
vaccines are lacking. In this review, we found 12 reports
including 614 patients that studied an adjuvanted non-live
vaccine [15, 16, 21, 26, 30, 35, 39, 41, 52–54, 59]. Seven
reports including 499 patients studied a non-adjuvanted non-
live vaccine [24, 25, 31, 32, 36, 56, 58]. It was unclear
whether the vaccine was adjuvanted in eight reports [19,
22, 23, 40, 42, 55, 57, 61]. No marked increase in disease
activity was seen in the patients receiving an adjuvanted
vaccine compared to the patients who received an
unadjuvanted dead composite vaccine. Based on these re-
sults, it does not seem likely that adjuvants cause a signifi-
cant deterioration of disease activity in paediatric patients
with rheumatic diseases.
In theory, adjuvants could also be part of the causal pathway
in the onset of AID. Anecdotal evidence for this relation has
been published [75, 76], and a syndrome of shared clinical
symptoms thought to be caused by adjuvants, the
autoimmune/inflammatory syndrome induced by adjuvants
(ASIA), has been postulated [76]. Recently, a large
epidemiological study applying the ASIA diagnostic criteria
to a population vaccinated with the HPV vaccine has been
performed. A total of 57 million administrated doses were re-
ported and 26,508 self-reports on AEs were found. Of these,
3932 cases could be classified as ASIA, defined by flu-like
symptoms such as fever, myalgia, arthralgia or arthritis. In
2634 cases, a probable or possible association with HPV vac-
cination could be made. However, no mention was made about
the duration of the complaints, and a comparison of the fre-
quency of similar complaints in an unvaccinated population
was not made [77].
Several large studies have not found any association be-
tween vaccination and AID. A large register-based cohort
study including 997,585 girls aged 10–17 years, amongwhom
296,826 received a total of 696,420 qHPV vaccine doses, no
association between exposure to the qHPV vaccine and auto-
immune adverse events was found [68•]. Also, analysis of
over 68,000 participants who received AS04-adjuvanted vac-
cines or served as controls demonstrated a low rate of autoim-
mune disorders, without evidence of an increase in relative
risk associated with AS04-adjuvanted vaccines [78]. Finally,
a review of reported adverse reactions after the pandemic in-
fluenza A/H1N1 vaccine using EudraVigilance data and liter-
ature did not reveal a difference between autoimmune phe-
nomena after adjuvanted or non-adjuvanted A/H1N1 vaccines
[79]. Thus, the possible relation between vaccine adjuvants
and the induction of autoimmune rheumatic diseases is thus
far not substantiated.
Discussion
The current systematic literature review found 21 articles on
vaccinations in pedRD published since the last systematic
literature from 2011. The new evidence, selected using the
same criteria as the first review, was added to the 27 previous-
ly described studies [12••].
Vaccines are generally immunogenic in patients with
pedRD. The validity of available evidence for the effect of
immunosuppressive drugs on immunogenicity was moderate
or low. To accurately assess the effect of a drug on the immu-
nogenicity of a vaccine, patients using these drugs need to be
compared to patients who are drug-free or are using a minimal
amount of immunosuppression. Few studies included such a
comparison, so only indirect conclusions on the effects of GC,
MTX and biologicals could be drawn. GC, predominantly
studied in a low dose (<20 mg/day), and MTX do not have
detrimental effects on the immune response. More evidence
has become available on the effect of biologicals, especially
anti-TNFα treatment, on (long-term) immunogenicity of vac-
cines. Although seroprotection rates are usually adequate, an-
tibody concentrations are lower in patients using biologicals.
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To ensure long-term protection against vaccine-
preventable infections, protective antibody levels should be
persistent. Persistence of protective antibody levels is lower
in pedRD patients than healthy controls for some, but not all,
pathogens [18, 22]. Biological use seems to accelerate the
natural decline of antibody levels, besides lowering the
vaccine-induced antibody concentrations. Therefore, regular
assessment of antibody levels and subsequent administration
of booster vaccines in these patients is important to ensure
long-term protection. Studies in healthy individuals suggest
that circulating antibody levels alone may not be predictive
of long-term protection, as cellular immunity can persist inde-
pendent of antibody levels [80, 81]. Assessment of cellular
memory in vaccinated pedRD patients could help to study
long-term protection against vaccine-preventable diseases.
Evidence on the efficacy (i.e. infection prevention) of vac-
cines in pedRD is still lacking. The studies that measured
infection rates in vaccinated and unvaccinated patients were
underpowered for definite conclusions on efficacy.
Regarding safety, vaccinations do not cause serious ad-
verse events. Disease activity is not influenced by vaccination
in the majority of the patients, now unequivocally shown for
the MMR vaccination in JIA patients and the VZV vaccina-
tion in jSLE patients. No evidence has been found that adju-
vants cause a higher disease activity in pedRD.
No vaccine-induced infections with live-attenuated viruses
were reported in vaccinated JIA or jSLE patients after
the MMR and VZV booster vaccination, respectively.
Therefore, it seems that these booster vaccinations can be
administered to pedRD patients, even in patients using bio-
logicals. BCG vaccinations should not be administered to pa-
tients on high-dose immunosuppressive drugs or biologicals
due to lack of safety data. Larger, controlled studies are nec-
essary to study rare serious adverse events, especially in pa-
tients on high-dose immunosuppressive drugs or biologicals.
Much information on vaccination in pedRD has been
gained in the time since the initial systematic review. For some
vaccines, high-quality studies have been performed that show
that they are generally immunogenic and safe. Additionally,
the need for (booster) vaccinations in pedRD has been illus-
trated by the papers published on reduced persistence of im-
munological memory over time.
More evidence on the influence of biologicals on the im-
mune response and safety of vaccines is required. Although
we have information on the immunogenicity of many vac-
cines, this does remain a surrogate endpoint. The efficacy,
namely a decrease in infection rates in pedRD, needs to be
studied in larger cohorts.
While more information will be gathered over the com-
ing years, we can now conclude that vaccinations in
pedRD should be advocated. Paediatric rheumatologists
should be pro-active in assessing protective antibody levels
in pedRD patients and should, in line with the EULAR-
recommendations, administer booster vaccines to children
who are not adequately protected.
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